U.S. Ends Pandemic Drug, Vaccine Contract With Emergent

The federal government and Emergent BioSolutions Inc. terminated a pandemic-preparedness contract after the contract drug manufacturer experienced problems manufacturing Covid-19 vaccines.

Emergent, based in Gaithersburg, Md., said Thursday the termination reduced the total value of its contract to $470.9 million from $650.8 million.


Leave a Reply

Your email address will not be published. Required fields are marked *

scroll to top